Erratum: Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma (Journal for ImmunoTherapy of Cancer (2020) 8 (e001235) DOI: 10.1136/jitc-2020-001235)

S. S. Neelapu, S. Adkins, S. M. Ansell

Research output: Contribution to journalComment/debatepeer-review

Abstract

Neelapu SS, Adkins S, Ansell SM, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma. J Immunother Cancer 2020;8:e001235. doi: 10.1136/jitc-2020-001235 In the Panel recommendations for Burkitt's lymphoma, the statement 'Options include rituximab+Lymphome Malins de Burkitt (R-LMB), rituximab+cyclophosphamide+ doxorubicin+methotrexate / ifosfamide+etoposide+cytarabine (R-CODOXM/ IVAC), DA-R- EPOCH, rituximab+ German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia Protocol (R-GMALL), and rituximab+cyclophosphamide+- doxorubicin+dexamethasone+pegfilgrastim alternating with rituximab+methotrexate+ cytarabine (R-HyperCAD)' has been corrected as below to add vincristine, omit pegfilgrastim and correct the acronym from 'R-HyperCAD' to 'R-HyperCVAD': 'Options include rituximab+Lymphome Malins de Burkitt (R-LMB), rituximab+cyclophosphamide+ doxorubicin+methotrexate / ifosfamide +etoposide+cytarabine (R-CODOXM/ IVAC), DA-R- EPOCH, rituximab+German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia Protocol (R-GMALL), and rituximab+cyclophosphamide+ vincristine+doxorubicin+dexamethasone alternating with rituximab+methotrexate+ cytarabine (R-HyperCVAD).

Original languageEnglish (US)
Article number001235
JournalJournal for ImmunoTherapy of Cancer
Volume9
Issue number1
DOIs
StatePublished - Jan 18 2021

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Molecular Medicine
  • Oncology
  • Pharmacology
  • Cancer Research

Fingerprint Dive into the research topics of 'Erratum: Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma (Journal for ImmunoTherapy of Cancer (2020) 8 (e001235) DOI: 10.1136/jitc-2020-001235)'. Together they form a unique fingerprint.

Cite this